SAFETY OF AND HUMORAL IMMUNE RESPONSE TO THE MERIAL RECOMBITEK CANINE DISTEMPER VIRUS VACCINE IN MANED WOLVES ().

Clicks: 249
ID: 79991
2020
Article Quality & Performance Metrics
Overall Quality Improving Quality
0.0 /100
Combines engagement data with AI-assessed academic quality
AI Quality Assessment
Not analyzed
Abstract
This study evaluated the safety of and humoral response to the Merial Recombitek recombinant canine distemper virus (rCDV) vaccine in maned wolves ( = 9, age 2-9 yr). All maned wolves had prior history of annual vaccination with the Merial Purevax ferret rCDV vaccine. Serum neutralization (SN) to CDV was measured prior to initial vaccination with the rCDV Recombitek vaccine followed by a booster vaccination at 4-6 wk. Final SN titers were obtained at 13 wk post initial vaccination. The maned wolves developed no observable adverse side effects through the study. Pre-Recombitek vaccination SN titers ranged from negative to 1: 8. Postvaccination CDV titers ranged from negative to 1: 8, and were therefore below the range of that considered protective in domestic dogs.
Reference Key
barrett2020safetyjournal Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Barrett, Colleen A;Joyner, Priscilla H;Anis, Eman;Wilkes, Rebecca P;Aitken-Palmer, Copper;
Journal Journal of zoo and wildlife medicine : official publication of the American Association of Zoo Veterinarians
Year 2020
DOI
10.1638/2017-0159
URL
Keywords
vaccine immune response canary-pox vector chrysocyon brachyurus canine distemper maned wolf

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.